Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) Accumulated Expenses (2016 - 2021)

Phio Pharmaceuticals' Accumulated Expenses history spans 10 years, with the latest figure at $2.1 million for Q3 2021.

  • For Q3 2021, Accumulated Expenses rose 49.89% year-over-year to $2.1 million; the TTM value through Sep 2021 reached $2.1 million, up 49.89%, while the annual FY2020 figure was $1.4 million, 40.25% up from the prior year.
  • Accumulated Expenses reached $2.1 million in Q3 2021 per PHIO's latest filing, down from $2.1 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $2.2 million in Q2 2018 to a low of $437000.0 in Q4 2018.
  • Average Accumulated Expenses over 5 years is $1.4 million, with a median of $1.4 million recorded in 2020.
  • The largest YoY upside for Accumulated Expenses was 120.59% in 2019 against a maximum downside of 64.89% in 2019.
  • A 5-year view of Accumulated Expenses shows it stood at $735000.0 in 2017, then plummeted by 40.54% to $437000.0 in 2018, then surged by 120.59% to $964000.0 in 2019, then skyrocketed by 40.25% to $1.4 million in 2020, then soared by 52.44% to $2.1 million in 2021.
  • Per Business Quant, the three most recent readings for PHIO's Accumulated Expenses are $2.1 million (Q3 2021), $2.1 million (Q2 2021), and $1.5 million (Q1 2021).